Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roivant Sciences

https://roivant.com/

Latest From Roivant Sciences

Myovant’s Relugolix Won’t Be Stopped By Missed Endpoint

The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.

Clinical Trials Cancer

Finance Watch: One Small Pain Drug Maker And Three Biotech SPACs Launch IPOs

After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m. 

Financing Growth

J&J Seeks Command Position In FcRn Space With Momenta Buyout

J&J will pay about $6.5bn to acquire Momenta and its potential “pipeline in a pathway” with nipocalimab. Analysts expect this deal may lead to further M&A activity in the anti-FcRn space.

M & A Deals

Finance Watch: New Funding Available For Antibacterials, Start-Ups

Private Company Edition: The Novo Holdings Repair Impact Fund wants to fund another round of antimicrobial resistance efforts. Also, Atlas Venture raised a new $400m fund, Everest closed a $310m series C round and Cognition received a $78.5m grant.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Altavant Sciences
    • Alyvant
    • Aruvant Sciences
    • Axovant Sciences
    • Cyotvant Sciences
    • Datavant
    • Dermavant Sciences
    • Enzyvant
    • Genevant
    • Immunovant Sciences
    • Metavant Sciences
    • PhaseRx
    • Respivant
    • Roivant Health
    • Roivant Neurosciences Ltd
    • Roivant Pharma
    • Roivant Sciences Ltd.
    • Inc.
    • Sinovant Sciences
    • Sumitovant Biopharma Ltd.
    • Valor Biotechnology
UsernamePublicRestriction

Register